Department of Pediatrics, University of Antioquia, Medellín, Colombia.
Hospital Pablo Tobón Uribe, Medellín, Colombia.
Pediatrics. 2020 Apr;145(4). doi: 10.1542/peds.2019-3260. Epub 2020 Mar 4.
Several antiemetics have been used in children with acute gastroenteritis. However, there is still controversy over their use.
To determine the effectiveness and safety of antiemetics for controlling vomiting in children with acute gastroenteritis.
Medline, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, Latin America and the Caribbean Literature on Health Sciences, and gray literature, until December 2018.
We selected randomized clinical trials comparing metoclopramide, ondansetron, domperidone, dexamethasone, dimenhydrinate, and granisetron.
Two reviewers independently screened abstracts and full texts, extracted the data, and assessed the risk of bias. We performed pairwise and network meta-analysis using the random-effects model.
Twenty-four studies were included (3482 children). Ondansetron revealed the largest effect in comparison to placebo for cessation of vomiting (odds ratio = 0.28 [95% credible interval = 0.16 to 0.46]; quality of evidence: high) and for hospitalization (odds ratio = 2.93 [95% credible interval = 1.69 to 6.18]; quality of evidence: moderate). Ondansetron was the only intervention that reduced the need for intravenous rehydration and the number of vomiting episodes. When considering side effects, dimenhydrinate was the only intervention that was worse than placebo.
Most treatment comparisons had low- or very low-quality evidence, because of risk of biases and imprecise estimates.
Ondansetron is the only intervention that revealed an effect on the cessation of vomiting, on preventing hospitalizations, and in reducing the need for intravenous rehydration. Ondansetron was also considered a safe intervention.
已有多种止吐药物被用于治疗儿童急性肠胃炎,但它们的使用仍存在争议。
评估止吐药物治疗儿童急性肠胃炎呕吐的疗效和安全性。
检索 Medline、Embase、Cochrane 对照试验中心注册库、护理学及相关健康领域文献累积索引、拉丁美洲和加勒比健康科学文献、灰色文献,检索时间截至 2018 年 12 月。
纳入比较甲氧氯普胺、昂丹司琼、多潘立酮、地塞米松、茶苯海明和格拉司琼的随机对照临床试验。
两位评价员独立筛选摘要和全文、提取资料并评估偏倚风险,采用随机效应模型进行二分类资料和网状 Meta 分析。
共纳入 24 项研究(3482 例患儿)。与安慰剂相比,昂丹司琼在停止呕吐(比值比=0.28,95%可信区间:0.160.46;证据质量:高)和住院(比值比=2.93,95%可信区间:1.696.18;证据质量:中)方面的效果最大。昂丹司琼是唯一能减少静脉补液和呕吐发作次数的干预措施。考虑到不良反应,只有茶苯海明比安慰剂差。
大多数治疗比较的证据质量为低或极低,因为存在偏倚风险和估计不精确。
昂丹司琼是唯一能有效缓解呕吐、减少住院和降低静脉补液需求的干预措施,且被认为是一种安全的干预措施。